Regulators of NFAT and/or store-operated calcium entry
Embodiments of the inventions relate to modulating NFAT activity, modulating store-operated Ca 2+ entry into a cell and treating and/or preventing hyperactivity or inappropriate immune response by inhibiting the expression or activities of proteins involved in the calcineurin/NFAT axis.
1. A method of modulating NFAT activity in a subject in need thereof, the method comprising administering a therapeutically effective amount of a pharmaceutical composition comprising an agent that inhibits the expression of a SEPT4 gene, wherein the agent is a nucleic acid inhibitor.
2. The method of claim 1 , wherein the nucleic acid inhibitor is an siRNA or shRNA.
3. A method of modulating store-operated Ca 2+ entry into a cell, the method comprising administering a therapeutically effective amount of a pharmaceutical composition comprising an agent that inhibits the expression of a SEPT4 gene, wherein the agent is a nucleic acid inhibitor.
4. The method of claim 3 , wherein the nucleic acid inhibitor is an siRNA or shRNA.
5. A method of treating and/or preventing hyperactivity or inappropriate immune response in a subject in need thereof, the method comprising administering a therapeutically effective amount of a pharmaceutical composition comprising an agent that inhibits the the expression of a SEPT4 gene, wherein the agent is a nucleic acid inhibitor.
6. The method of claim 5 , wherein the hyperactivity or inappropriate immune response in a subject is associated with acute and chronic immune diseases selected from a group consisting of asthma, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, rheumatoid arthritis, insulin-dependent diabetes, inflammatory bowel disease, autoimmune thyroiditis, hemolytic anemia, multiple sclerosis, transplant graft rejections and graft-versus-host disease.
7. The method of claim 5 , wherein the nucleic acid inhibitor is an siRNA or shRNA.